PICOS Score May Help in Identification of Patients with Brain Metastasis at High Risk for VTEs
Thrombogenicity of primary tumour, immobilisation, chemotherapy, obesity and steroid use are independently associated with venous thromboembolic events
Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
Thrombogenicity of primary tumour, immobilisation, chemotherapy, obesity and steroid use are independently associated with venous thromboembolic events
Efficacy and safety were supported by data from the AAML0531 study
FDA also approved the cobas EZH2 Mutation Test as a companion diagnostic for tazemetostat
Efficacy was demonstrated in the PM1183-B-005-14 study
Findings from the MSKCC series
FDA also approved a companion diagnostic for pembrolizumab
JAK inhibitor shows promise in a patient with refractory immune-related complication of pembrolizumab
Evidence for efficacy is based on the results from the ATTRACTION-3 trial
It was intended for the treatment of non-small-cell lung cancer and pancreatic cancer
Evidence for efficacy is based on the results from the RELAY study
Results of first-line maintenance avelumab plus best supportive care reported at ASCO 2020 Virtual Meeting
Findings from two Chinese multicentre, retrospective, cohort studies
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.